Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 550

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 550
---
 Following the Merger, such communications should be sent in care of NLS Pharmaceutics Ltd. at The Circle6, 8058 Zurich, Switzerland, and its telephone number is +41.44.512.2150. Each communication will be forwarded, depending on the subject matter, to the NLS Board, the appropriate committee chairperson or all non -managementdirectors. LEGAL MATTERS Certain legal matters concerning this proxy statement/prospectus will be passed upon for us by Sullivan & Worcester LLP, New York, New York. Certain legal matters with respect to Swiss law will be passed upon for us by Baker McKenzie Switzerland AG, Zurich, Switzerland. Certain legal matters with respect to Kadimastem and Israeli law will be passed upon for us by Pearl Cohen Zedek Latzer Baratz LLP. EXPERTS The financial statements of NLS Pharmaceutics Ltd. as of December31, 2023 and for each of the two years in the period ended December31, 2023 included in this proxy statement/prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to NLS’s ability to continue as a going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers AG, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The financial statements of NLS Pharmaceutics Ltd. included in this proxy statement/prospectus for the year ended December31, 2024 have been so included in reliance on the report (which contains an explanatory paragraph relating to NLS’s ability to continue as a going concern as described in Note 1 to the financial statements) of Marcum LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The financial statements of Kadimastem Ltd. as of December31, 2024 and for each of the three years in the period ended December 31, 2024 included in this proxy statement/prospectus, have been audited by Kost Forer Gabbay & Kasierer, a Member of EY Global, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about Kadimastem Ltd.’s ability to continue as a going concern as described in Note 1B to the financial statements) and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon